Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt ...

With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate deal with Viatris.

Viatris is one of the largest generic drug manufacturers in the world. Generic drugs make up about 40% of the firm's sales and, along with other generics manufacturers, they continues to suffer ...

Zooming in further, Viatris has lagged behind the SPDR S&P Pharmaceuticals ETF’s 6.3% gains over the past 52 weeks and 4.8% return in 2025. On Nov. 7, Viatris announced its third-quarter ...

Viatris (NASDAQ:VTRS) is scheduled to announce Q4 earnings results on Thursday, February 27th, before market open. SA analyses from early this year have ranged from cautious to optimistic ...

Despite operational successes, Viatris faced a significant 71% drop in GAAP net earnings due to international market pressures. Viatris delivered a mixed quarter, topping earnings expectations but ...

CANONSBURG, Pa. (AP) — CANONSBURG, Pa. (AP) — Viatris Inc (VTRS) on Thursday reported a loss of $516.5 million in its fourth quarter. The Canonsburg, Pennsylvania-based company said it had a ...